Viatris’ Dividend Has Room to Grow, but Will Management Deliver?
Viatris Inc. (NASDAQ:VTRS) is a familiar name in the pharmaceutical industry, with a portfolio that stretches from branded medications to generics and fresh, innovative therapies.
Viatris Inc (VTRS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 34,168,743 | $542,599,639 | +2% | 4.98% |
| 2. | Deerfield Management James E. Flynn | 20,206,170 | $320,873,980 | 3.35% | |
| 3. | Glenview Capital Larry Robbins | 9,877,409 | $156,853,255 | +9% | 2.86% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 8,371,218 | $132,934,942 | -3% | 0.06% |
| 5. | Callodine Capital Management James Morrow | 8,000,742 | $127,051,783 | -2% | 8.29% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.43 | 213 | $2,220.63 | 1,183 | 2025-11-03 | Filing | |
| $10.42 | 286 | $2,980.98 | 970 | 2025-08-27 | Filing | |
| $9.99 | 22,000 | $219,740.40 | 314,807 | 2025-08-12 | Filing | |
| $8.94 | 60,000 | $536,262.00 | 292,807 | 2025-05-12 | Filing | |
| $9.01 | 19 | $171.13 | 94,960 | 2023-10-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.17 | 50,076 | $809,784.00 | 316,212 | 2026-06-25 | Filing | |
| $13.28 | 21,350 | $283,538.68 | 366,288 | 2026-03-23 | Filing | |
| $10.25 | 7,032 | $72,044.95 | 35,299 | 2025-09-11 | Filing | |
| $12.88 | 26,925 | $346,686.30 | 126,901 | 2024-11-11 | Filing | |
| $11.66 | 139,681 | $1,628,163.64 | 505,838 | 2024-09-12 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,533,840 | $186,659,645 | 0.18% | |
| 2. | 3,750,761 | $66,463,491 | 2.12% | |
| 3. | 1,820,427 | $32,257,964 | 0.04% | |
| 4. | 1,679,856 | $29,767,048 | 0.54% | |
| 5. | 1,493,954 | $26,472,865 | 0.46% |
News See All
Top 10 Unstoppable Dividend Stocks to Buy
Dividend cuts have been a major concern for income investors. It is easy to see why they dislike dividend reductions, suspensions, and eliminations.
10 Best US Stocks to Buy Under $20: Ranked by Hedge Funds
Rising bond yields have put pressure on small-cap stocks, driving the Russell 2000 Index’s longest weekly losing streak since May 2022.
Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?
Viatris Inc. (NASDAQ:VTRS) and Opus Genetics, Inc. (NASDAQ:IRD) are waiting on the same decision.
Why Is Pacira Pharmaceuticals Stock (PCRX) Up 44% Today?
Pacira Pharmaceuticals stock rallied over 44% on Thursday alongside news of a merger agreement with Viatris.
Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks
The recent breakout of Moderna reminded investors that AI stocks aren't the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely.
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million.
10 Most Undervalued NASDAQ Stocks to Buy Right Now
In this article, we will discuss the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On July 1, Palantir CEO Alex Karp joined CNBC's 'Squawk Box' to discuss Palantir's deal with NVIDIA.
Top 10 Extreme Value Stocks To Buy Now
In this article, we will look at the Top 10 Extreme Value Stocks To Buy Now.
Hedge Fund Resource Center